Industry News
Zilico's cervical cancer diagnostic device lands CE Mark
Oct 07, 2013
Zilico Ltd has received EC certification from its Notified Body for its cervical cancer diagnostics device, ZedScan I. The UK company's ground-breaking system offers quicker and more accurate detection of cervical neoplasia in real-time, enabling clinicians to improve patient management. The ZedScan I system is used alongside colposcopy on women identified with an abnormal smear result... Read More
Cornerstone pharmaceuticals receives FDA orphan drug designation of CPI-613 for treatment of myelodysplastic syndrome
Oct 07, 2013
Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613, the Company's lead Altered Energy Metabolism Directed (AEMD) drug candidate, for the treatment of myelodysplastic syndrome (MDS)... Read More
Zilico's cervical cancer diagnostic device lands CE Mark
Oct 07, 2013
Zilico Ltd has received EC certification from its Notified Body for its cervical cancer diagnostics device, ZedScan I. The UK company's ground-breaking system offers quicker and more accurate detection of cervical neoplasia in real-time, enabling clinicians to improve patient management. The ZedScan I system is used alongside colposcopy on women identified with an abnormal smear result... Read More
Walking tied to lower risk for breast cancer
Oct 07, 2013
A large study published recently in the journal Cancer Epidemiology, Biomarkers, and Prevention found that walking was linked to a lower risk for breast cancer in women who have gone through menopause, and for whom walking was their only form of physical activity in leisure time. The findings add to a growing pile of evidence linking regular exercise with lower risk for breast cancer... Read More
Cornerstone pharmaceuticals receives FDA orphan drug designation of CPI-613 for treatment of myelodysplastic syndrome
Oct 07, 2013
Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613, the Company's lead Altered Energy Metabolism Directed (AEMD) drug candidate, for the treatment of myelodysplastic syndrome (MDS)... Read More
A one-two punch against cancer: American Chemical Society podcast
Oct 07, 2013
The latest episode in the American Chemical Society's (ACS') award-winning Global Challenges/Chemistry Solutions podcast series* describes the development and successful lab tests on the first potential drug to pack a lethal one-two punch against melanoma skin cancer cells. Based on a report by Nathan Luedtke, Ph.D... Read More
Vaccine acceptance put at risk by neglect of 'science communication environment'
Oct 07, 2013
The biggest threat to the contribution that childhood vaccines make to societal well-being doesn't come from deficits in public comprehension, distrust of science, or misinformation campaigns, but rather from the failure of governmental and other institutions to use evidence-based strategies to anticipate and avoid recurring threats to the science communication environment - th... Read More
Active ingredient of ipecac syrup inhibits growth of bladder cancer cells
Oct 07, 2013
An old home remedy called ipecac syrup, once stocked in medicine cabinets in case of accidental poisoning, is showing promise as a new chemotherapy drug for bladder cancer. Years ago ipecac syrup was used to induce vomiting in poisoning cases... Read More
A one-two punch against cancer: American Chemical Society podcast
Oct 07, 2013
The latest episode in the American Chemical Society's (ACS') award-winning Global Challenges/Chemistry Solutions podcast series* describes the development and successful lab tests on the first potential drug to pack a lethal one-two punch against melanoma skin cancer cells. Based on a report by Nathan Luedtke, Ph.D... Read More
Vaccine acceptance put at risk by neglect of 'science communication environment'
Oct 07, 2013
The biggest threat to the contribution that childhood vaccines make to societal well-being doesn't come from deficits in public comprehension, distrust of science, or misinformation campaigns, but rather from the failure of governmental and other institutions to use evidence-based strategies to anticipate and avoid recurring threats to the science communication environment - th... Read More
Previous Page Next Page